Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincenza Conteduca

Showing results (61-70 of 157) with videos related to

Pageof 16
Sort By:
Frontiers in Pharmacology|October 30, 2016
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with AbirateroneCristian Lolli, Orazio Caffo, Emanuela Scarpi, et al.
The Prostate|May 19, 2015
Metabolic syndrome in castration-resistant prostate cancer patients treated with abirateroneVincenza Conteduca, Orazio Caffo, Lisa Derosa, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 27, 2015
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamideUgo De Giorgi, Paola Caroli, Emanuela Scarpi, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2025
YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate CancerVicenç Ruiz de Porras, Martin K Bakht, Maria Fernandez-Saorín, et al.
International Journal of Molecular Sciences|July 27, 2022
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent DifferentiationFrancesca Sanguedolce, Magda Zanelli, Andrea Palicelli, et al.
Molecular Oncology|October 17, 2021
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcomeVincenza Conteduca, Emanuela Scarpi, Paola Caroli, et al.
International Journal of Molecular Sciences|December 6, 2017
Immunotherapy for Prostate Cancer: Where We Are HeadedGiuseppe Schepisi, Alberto Farolfi, Vincenza Conteduca, et al.
Oncotarget|May 19, 2016
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancerSamanta Salvi, Valentina Casadio, Vincenza Conteduca, et al.
Cancers|March 6, 2021
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell TherapyGiuseppe Schepisi, Chiara Casadei, Ilaria Toma, et al.
International Journal of Molecular Sciences|June 2, 2021
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic ReviewGiuseppe Schepisi, Caterina Gianni, Sara Bleve, et al.
Pageof 16

Showing results (61-70 of 157) with videos related to

Sort By:
Pageof 16
Frontiers in Pharmacology|October 30, 2016
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with AbirateroneCristian Lolli, Orazio Caffo, Emanuela Scarpi, et al.
The Prostate|May 19, 2015
Metabolic syndrome in castration-resistant prostate cancer patients treated with abirateroneVincenza Conteduca, Orazio Caffo, Lisa Derosa, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 27, 2015
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamideUgo De Giorgi, Paola Caroli, Emanuela Scarpi, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2025
YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate CancerVicenç Ruiz de Porras, Martin K Bakht, Maria Fernandez-Saorín, et al.
International Journal of Molecular Sciences|July 27, 2022
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent DifferentiationFrancesca Sanguedolce, Magda Zanelli, Andrea Palicelli, et al.
Molecular Oncology|October 17, 2021
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcomeVincenza Conteduca, Emanuela Scarpi, Paola Caroli, et al.
International Journal of Molecular Sciences|December 6, 2017
Immunotherapy for Prostate Cancer: Where We Are HeadedGiuseppe Schepisi, Alberto Farolfi, Vincenza Conteduca, et al.
Oncotarget|May 19, 2016
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancerSamanta Salvi, Valentina Casadio, Vincenza Conteduca, et al.
Cancers|March 6, 2021
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell TherapyGiuseppe Schepisi, Chiara Casadei, Ilaria Toma, et al.
International Journal of Molecular Sciences|June 2, 2021
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic ReviewGiuseppe Schepisi, Caterina Gianni, Sara Bleve, et al.
Pageof 16